ES104 (Not yet branded)
Other Medications
Description
ES104 is a novel therapeutic agent currently in early-phase clinical development for patients with metastatic colorectal cancer. This compound represents a new approach to treating advanced CRC, specifically designed for patients whose disease has spread beyond the primary site. Based on its designation and clinical trial focus, ES104 appears to be a targeted therapy developed for patients with limited treatment options in the metastatic setting.
Mechanism of Action
The specific molecular mechanism of action for ES104 has not been publicly disclosed in available clinical trial documentation. As an early-phase compound, detailed mechanistic information regarding its cellular targets and pathway interactions remains proprietary pending completion of ongoing clinical studies.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.